← All trials
NCT04925284
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 7, 2021
- Primary completion
- Jun 7, 2024
- Completion date
- Oct 7, 2024
- First posted
- Jun 14, 2021
- Last posted
- Nov 17, 2021
- Enrollment
- 199
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ExelixisLead sponsor
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Ovarian Epithelial
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Neoplasms
- Pancreatic Neoplasms
- Endometrial Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.